Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.57 |
| ▸ | SQLE | Q14534 | 4/20 | 0.55 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12215437 | 1.00 | KMT2A (0.64) | KMT2AKDM4EMAPTMEN1CYP3A4 | |
| SCHEMBL2568888 | 1.00 | KMT2A (0.64) | KMT2AKDM4EMAPTMEN1CYP3A4 | |
| SCHEMBL16125783 | 1.00 | KMT2A (0.64) | KMT2AKDM4EMAPTMEN1CYP3A4 | |
| SCHEMBL2496380 | 1.00 | KMT2A (0.64) | KMT2AKDM4EMAPTMEN1CYP3A4 | |
| SCHEMBL2495543 | 1.00 | KMT2A (0.64) | KMT2AKDM4EMAPTMEN1CYP3A4 | |
| SCHEMBL8978505 | 1.00 | KMT2A (0.64) | KMT2AKDM4EMAPTMEN1CYP3A4 | |
| SCHEMBL2495546 | 1.00 | KMT2A (0.64) | KMT2AKDM4EMAPTMEN1CYP3A4 | |
| SCHEMBL2496377 | 1.00 | KMT2A (0.64) | KMT2AKDM4EMAPTMEN1CYP3A4 | |
| SCHEMBL8978471 | 1.00 | KMT2A (0.64) | KMT2AKDM4EMAPTMEN1CYP3A4 | |
| SCHEMBL11150734 | 1.00 | KMT2A (0.64) | KMT2AKDM4EMAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126060-B2 | Cosmetic use of geranylgeranyl-2-propanol | SEDERMA (FR) | 2015-09-08 | — | — | US | claimed |
| EP-2555743-B1 | COSMETIC USE OF GERANYLGERANYL-2-PROPANOL | SEDERMA SA (FR) | 2015-09-02 | — | — | EP | claimed |
| US-20130058878-A1 | Cosmetic Use Of Geranylgeranyl-2-Propanol | SEDERMA (FR) | 2013-03-07 | — | — | US | claimed |
| EP-2555743-A2 | COSMETIC USE OF GERANYLGERANYL-2-PROPANOL | Sederma (FR) | 2013-02-13 | — | — | EP | claimed |
| WO-2011125039-A2 | COSMETIC USE OF GERANYLGERANYL-2-PROPANOL | SEDERMA (FR) | 2011-10-13 | — | — | WO | claimed |
| EP-0046995-B1 | 6,10,14,18-TETRAMETHYL-5,9,13,17-NONADECATETRAENE-2-OL, A PROCESS FOR PRODUCING SAME AND A PHARMACEUTICAL COMPOSITION | Eisai Co., Ltd. (JP) | 1983-05-25 | — | — | EP | claimed |
| US-4382151-A | 6,10,14,18-Tetramethly-5,9,13,17-nonadecatetraene-2-ol | EISAI CO., LTD. (JP) | 1983-05-03 | — | — | US | claimed |
| EP-0046995-A1 | 6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraene-2-ol, a process for producing same and a pharmaceutical composition | Eisai Co., Ltd. (JP) | 1982-03-10 | — | — | EP | claimed |
| JP-57042643-A | — | — | None | — | — | JP | disclosed |
| CN-107501070-B | Refining method of teprenone and intermediate thereof | 成都国为生物医药有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2017112441-A1 | METHOD OF COUNTERACTING THE IMPACT OF CHRONIC STRESS ON SKIN | ELC MANAGEMENT LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170172909-A1 | Method Of Counteracting The Impact Of Chronic Stress On Skin | ELC MANAGEMENT LLC | 2017-06-22 | — | — | US | disclosed |
| US-9126060-B2 | Cosmetic use of geranylgeranyl-2-propanol | SEDERMA (FR) | 2015-09-08 | — | — | US | disclosed |
| US-9126060-B2 | Cosmetic use of geranylgeranyl-2-propanol | SEDERMA (FR) | 2015-09-08 | — | — | US | disclosed |
| US-4382151-A | 6,10,14,18-Tetramethly-5,9,13,17-nonadecatetraene-2-ol | EISAI CO., LTD. (JP) | 1983-05-03 | — | — | US | disclosed |
| US-4382151-A | 6,10,14,18-Tetramethly-5,9,13,17-nonadecatetraene-2-ol | EISAI CO., LTD. (JP) | 1983-05-03 | — | — | US | disclosed |
| JP-S5742643-A | 6,10,14,18-TETRAMETHYL-5,9,13,17-NONADECATETRAENE-2-OL | EISAI CO LTD | 1982-03-10 | — | — | JP | disclosed |
| EP-0046995-A1 | 6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraene-2-ol, a process for producing same and a pharmaceutical composition | Eisai Co., Ltd. (JP) | 1982-03-10 | — | — | EP | disclosed |
| EP-0046995-A1 | 6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraene-2-ol, a process for producing same and a pharmaceutical composition | Eisai Co., Ltd. (JP) | 1982-03-10 | — | — | EP | disclosed |
| EP-0046995-A1 | 6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraene-2-ol, a process for producing same and a pharmaceutical composition | Eisai Co., Ltd. (JP) | 1982-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130058878-A1 | Cosmetic Use Of Geranylgeranyl-2-Propanol | TERT, GLA, TELO2 | KMT2A 3544/4885KDM4E 3491/4885MAPT 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.